ESR2 and prostate carcinoma: All results confirmed how ERβ reduced androgen-independent prostate cancer cells’ viability and induced apoptosis through downregulation of anti-apoptotic proteins Survivin and Bcl-2 mediated by TGFβ1 and/or IGF1 signaling pathway [189].